


FORM PTO-1390 (REV 11-2000)	U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 1721-47
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO (If known, see 37 C.F.R. 1.5) 10/048116
INTERNATIONAL APPLICATION NO. PCT/FR00/02193	INTERNATIONAL FILING DATE 28 July 2000	PRIORITY DATE CLAIMED 29 July 1999
TITLE OF INVENTION RECOMBINANT PROTEINS AND MOLECULAR COMPLEXES DERIVED FROM THESE PROTEINS, ANALOGOUS TO MOLECULES INVOLVED IN IMMUNE RESPONSES		
APPLICANT(S) FOR DO/EO/US GLAICHENHAUS et al		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The U.S. has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input checked="" type="checkbox"/> A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 To 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information. 		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.15) 107048116			INTERNATIONAL APPLICATION NO. PCT/FR00/02193	ATTORNEY'S DOCKET NUMBER 1721-47																									
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY																									
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5): <ul style="list-style-type: none"> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$890.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO..... \$740.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00 																													
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 890.00																									
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$ 130.00																									
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> <th></th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>11</td> <td>-20 =</td> <td>X \$18.00</td> <td>\$ 0.00</td> </tr> <tr> <td>Independent Claims</td> <td>1</td> <td>-3 =</td> <td>X \$84.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIMS(S) (if applicable)</td> <td>\$280.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td style="text-align: right;">\$ 1020.00</td> </tr> </tbody> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total Claims	11	-20 =	X \$18.00	\$ 0.00	Independent Claims	1	-3 =	X \$84.00	\$ 0.00	MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$280.00	\$ 0.00	TOTAL OF ABOVE CALCULATIONS =				\$ 1020.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																										
Total Claims	11	-20 =	X \$18.00	\$ 0.00																									
Independent Claims	1	-3 =	X \$84.00	\$ 0.00																									
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$280.00	\$ 0.00																									
TOTAL OF ABOVE CALCULATIONS =				\$ 1020.00																									
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				0.00																									
				SUBTOTAL = \$ 1020.00																									
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)). + 0.00																													
				TOTAL NATIONAL FEE = \$ 1020.00																									
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property + \$ 0.00																													
Fee for Petition to Revive Unintentionally Abandoned Application (\$1280.00 - Small Entity = \$640.00) \$ 0.00																													
				TOTAL FEES ENCLOSED = \$ 1020.00																									
				Amount to be: refunded \$ Charged \$																									
a. <input checked="" type="checkbox"/> A check in the amount of \$1020.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$ _____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A <u>duplicate</u> copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.																													
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																													
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000																													
 SIGNATURE																													
B. J. Sadoff NAME _____																													
36,663 January 28, 2002 REGISTRATION NUMBER Date																													

10043 1/4416

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 24 MAY 2002

In re Patent Application of
GLAICHENHAUS et al

Serial No. 10/048,116

Filed: January 28, 2002

Atty. Ref.: 1721-47

Group:

Examiner:

For: RECOMBINANT PROTEINS AND MOLECULAR COMPLEXES DERIVED FROM THESE PROTEINS, ANALOGOUS TO MOLECULES INVOLVED IN IMMUNE RESPONSES

May 24, 2002

Honorable Assistant Commissioner of Patents
Washington, DC 20231

Sir:

STATEMENT

The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

B. J. Gaden
Reg. No. 36 663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GLAICHENHAUS et al

Atty. Ref.: 1721-47

Serial No. 10/048,116

Group:

Filed: January 28, 2002

Examiner:

For: RECOMBINANT PROTEINS AND MOLECULAR
COMPLEXES DERIVED FROM THESE PROTEINS,
ANALOGOUS TO MOLECULES INVOLVED IN IMMUNE
RESPONSES

* * * * *

May 24, 2002

Honorable Assistant Commissioner of Patents
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Notification dated April 10, 2002, entry and consideration of
the following amendments and remarks are requested.

IN THE SPECIFICATION:

Amend the specification as follows:

Insert the attached Sequence Listing after the claims pages.

REMARKS

Reconsideration is requested.

Responsive to the Notification dated April 10, 2002, the applicants submit that
the requisite Declaration was filed February 27, 2002. A copy of the previously filed
Declaration and the undersigned's cover sheet which was filed therewith on February
27, 2002 is attached for the convenience of the Office. A copy of the undersigned's

In re Application of: GLAICHENHAUS et al
Serial No. 10/048,116

post card receipt from the filing of February 27, 2002 is attached as evidence the same was received by the Patent Office on February 27, 2002.

A copy of the Notification dated April 10, 2002 is attached.

The specification has been amended to include the attached Sequence Listing.


The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added. A separate Statement to this effect is attached.

An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

200416446 10/048116

501 Recd/PCT 28 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GLAICHENHAUS et al

Atty. 1721-47

Serial No. Unknown

Ref.:

Group:

National Phase of: PCT/FR00/02193

International Filing Date: 28 July 2000

Filed: **Herewith**

Examiner:

For: **RECOMBINANT PROTEINS AND MOLECULAR COMPLEXES
DERIVED FROM THESE PROTEINS, ANALOGOUS TO
MOLECULES INVOLVED IN IMMUNE RESPONSES**

* * * * *

January 28, 2002

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Prior to calculation of the filing fee and in order to place the above identified application in better condition for examination, please amend as follows:

IN THE SPECIFICATION

Page 1, after the title insert the following:

-- This application is the US national phase of international application PCT/FR00/02193 filed July 28, 2000 which designated the U.S. --.

IN THE CLAIMS (AS AMENDED)

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

GLAICHENHAUS et al
Serial No. Unknown
U.S. National Phase of PCT/FR00/02193

4. (Amended) Nucleotide sequences having a reading frame corresponding to all or part of a protein according to claim 1.

7. (Amended) Use of proteins according to claim 2, for counting and/or purifying the T lymphocytes that react with a given antigen and for characterizing the phenotype of these cells.

10. (Amended) Use according to claim 2, for the purification and/or enrichment of specific T lymphocytes of a given antigen, either from cell cultures, or from samples taken from a patient.

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

The above amendments are made to place the claims in a more traditional format.

The above amendments are based on the claims as amended in the International phase of the PCT application. A two page translation of a set of 11 claims is attached and should be the basis for the above amendments and the subject of the initial examination, unless the application is further amended in subsequently submitted papers. An English translation of the originally published application and set of 16 numbered claims is also attached, for completeness and in compliance with the rules and statute. An English translation of an Abstract is


GLAICHENHAUS et al
Serial No. Unknown
U.S. National Phase of PCT/FR00/02193

also attached, as a separate sheet for insertion in the application in a manner deemed appropriate by the Patent Office.

The present filing is submitted to meet the requirements of 35 U.S.C. § 371 but for the submission of an executed Declaration. The Office is requested to contact the undersigned if anything further is required in this regard.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

B. J. Sadoff

Reg. No. 36,663

BJS:lmv

1100 North Glebe Road, 8th
Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

597171

GLAICHENHAUS et al

Serial No. Unknown

U.S. National Phase of PCT/FR00/02193

የኢትዮጵያ ቤት የዕለታዊ የስራ የዕለታዊ የስራ የዕለታዊ የስራ የዕለታዊ የስራ

10/048116

531 Rec'd PCT/F 28 JAN 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

4. (Amended) Nucleotide sequences having a reading frame corresponding to all or part of a protein according to [any one of claims 1 to 3] claim 1.

7. (Amended) Use of proteins according to claim 2 [or 3], for counting and/or purifying the T lymphocytes that react with a given antigen and for characterizing the phenotype of these cells.

10. (Amended) Use according to claim 2 [or 3], for the purification and/or enrichment of specific T lymphocytes of a given antigen, either from cell cultures, or from samples taken from a patient.

531 Rec'd PCT/FT 28 JAN 2002

Recombinant proteins and molecular complexes derived from these proteins, analogous to molecules involved in immune responses.

5 The invention relates to recombinant proteins, and to molecular complexes derived from these proteins, analogous to molecules involved in immune responses.

10 It also relates to a method for producing such molecules and of such complexes, as well as their uses, in particular for diagnosis and in therapy.

It is known that molecules encoded by the Major Histocompatibility Complex (MHC) have a major role in an immune response.

15 These molecules are made up of two polypeptide chains: the heavy chain, and the light chain.

20 The molecules of the MHC are expressed on the surface of the presenting cells (dendritic cells, B lymphocytes, macrophages) in the form of molecular complexes with antigenic peptides, which are in turn derived from extracellular or intracellular proteins.

Recognition of these peptide/MHC complexes by a specific receptor expressed on the surface of the T lymphocytes is at the origin of any cell-mediated immune response.

25 The MHC molecules belong to two separate classes: those of class I, which are recognized by CD8⁺ T lymphocytes (cytotoxic T cells) and those of class II which are recognized by CD4⁺ T lymphocytes (helper T cells).

30 In order to be able to be used as probes for counting and measuring the frequency of specific T lymphocytes of a given antigen, such molecules and complexes have to be produced in soluble form. These same soluble molecules and complexes can be used for modulating the immune responses.

The possibility of using soluble MHC molecules for detecting CD8⁺ T lymphocytes was first demonstrated by Altman et al. in 1996 (1). Since then, many teams have used this strategy for counting and characterizing the phenotype 5 of CD8⁺ T lymphocytes reacting with viral or bacterial peptides or peptides derived from tumour antigens. However, the application of this strategy for the detection of CD4⁺ T lymphocytes has proved problematic.

In the majority of works published to date, bacterial 10 expression systems have been used for producing class I MHC molecules. After incubation of these molecules with antigenic peptides, the peptide/MHC complexes were purified and obtained in the form of tetramers after incubation with streptavidin. This last stage is made possible by addition, 15 to the carboxy-terminal end of the MHC heavy chain, of a recognition site for the BirA enzyme, a bacterial enzyme that is capable of catalysing the addition of a biotin molecule. Other teams chose to produce dimers of class I MHC molecules by using the skeleton of an antibody. In this case 20 the MHC heavy chain was bound to the heavy chain of an immunoglobulin (abbreviated to Ig) and β -2-microglobulin was bound to the light chain. As the Fc regions of the heavy chains link together by means of sulphide bridges, the molecules produced are dimers of MHC molecules.

25 For technical reasons, the preparation of molecular probes that bind selectively to the CD4⁺ T lymphocytes proved much more difficult, probably because of the intrinsic instability of the class II MHC molecules.

Tetramers of class II molecules bound to an antigenic 30 peptide, or dimers of these molecules obtained using the skeleton of an antibody, have been produced.

The problem of the stability and affinity of the receptors of CD4⁺ T lymphocytes for their ligand is solved, according to the invention, by employing constructs ensuring

the formation of dimers giving multivalent complexes owing to the use of molecules having several binding sites for certain regions of the dimers.

Such constructs can be envisaged both for class I MHC 5 molecules and for those of class II.

Advantageously, the said constructs are sufficiently stable for use as molecular probes, thus opening up a wide field of application.

These constructs can also be used for obtaining 10 analogues of T cell receptors capable of specifically recognizing such molecules.

The invention therefore aims to supply recombinant molecules and corresponding recombinant complexes, in which these molecules are bound to antigenic peptides, of great 15 stability and with high affinity for their ligand.

Another aim is their production in host cells with the aid of suitable expression vectors.

A further aim of the invention relates to immunological applications of these complexes as molecular probes.

20 The soluble recombinant proteins according to the invention are constituted, as a minimum, from a dimer, itself formed from α and β chains of class I or II MHC molecules.

Other soluble recombinant proteins according to the 25 invention are constituted, as a minimum, from a dimer, itself formed from two proteins each of which is made up of the whole or a fused part of alpha and beta chains of class I or II MHC molecules.

These dimers are characterized in that they have, at 30 the carboxy terminal end of one or both chains, the whole or part of an Fc region of an immunoglobulin.

"Part of an Fc region" denotes a fragment corresponding to a natural fragment, or one modified relative to the said natural fragment, by substitution and/or by deletion and/or

by mutation, but capable of binding to a protein possessing binding sites for the Fc region, such as protein A or protein G.

The term "capable of binding" is illustrated by Example 5 1C.

The Fc region corresponds more particularly to the whole or part of the CH₂ and/or CH₃ domain. This domain can be modified relative to the natural domain, but must be capable, in accordance with the invention, of binding to a 10 protein of the protein A or G type possessing several binding sites for the Fc region of an Ig.

The immunoglobulin having the constant region mentioned above can be an IgG, especially the isotypes IgG1, IgG2a, IgG2b, IgG3, an IgM, and IgA, and IgD or an IgE.

15 The proteins of the invention are more particularly characterized in that they comprise all or part of the α or β chains of the MHC molecules.

Advantageously, the α and β chains constituting the dimer contain leucine zippers, which promotes their pairing.

20 Such leucine zippers are described for example by Scott et al. (2) or Kalandadze et al. (3).

The invention relates in particular to recombinant molecules bound together as several dimers and particularly as tetramers and quite especially as octamers.

25 The said recombinant molecules are complexed with a natural or artificial protein comprising several binding sites for the constant regions of the immunoglobulins and thus permitting the creation of multimers from dimers. As an example protein A which is commonly isolated from 30 *Staphylococcus aureus*, or protein G from *Streptococcus* (group C), or receptor multimers from the Fc regions obtained by genetic recombination can be mentioned.

The recombinant molecules as defined above, complexed to antigenic peptides, constitute MHC analogues. These are soluble recombinant proteins, characterized in that they are bound covalently or non-covalently to an antigenic peptide.

5 The invention relates to the said complexes, characterized in that they have, at the $-\text{NH}_2$ end of the β chain, an antigenic peptide that is fixed by means of a flexible arm. This arm can be of a variable length and makes it possible to locate the antigenic peptide in the groove formed by the

10 or each dimer. Fixations of this kind are described for example by Kozono et al. (4) and (5).

The molecules defined above are preferably obtained by the techniques described in textbooks of molecular biology for the preparation of recombinant genes and their

15 expression in eukaryotic or prokaryotic cells. Reference should be made for example to the works of Sambrook et al. (6) or of Ausubel et al. (7).

The nucleotide sequences of the invention possess a reading frame corresponding to the whole or part of a

20 protein as defined above.

The sequences coding for the recombinant fragments constituting the molecules defined above are introduced into expression vectors. Generally as many expression vectors as fragments are used. However, it is also possible, as a

25 variant, to use an identical vector for several fragments. Plasmids and especially plasmids possessing a selection marker will be used advantageously as expression vectors. Satisfactory expression results have thus been obtained with plasmids that are able to replicate in bacteria and have, as

30 selection marker, an antibiotic resistance gene.

The promoters will be selected so as to permit expression of the recombinant gene in the expression system used. As an example the promoter recognized by the polymerase of the T4 bacteriophage or, when using Drosophila

cells as the expression system, the promoter of the metallothionein gene may be mentioned.

As eukaryotic expression systems, we may mention the recombinant baculovirus systems in insect cells, *Drosophila* 5 cells, hamster cells (CHO line) and monkey cells (COS line). It is also possible to effect expression in yeast cells.

Bacteria are widely used, in particular *E. coli*, as prokaryotic expression systems.

The recombinant molecules produced are purified on 10 immunoaffinity columns, especially with monoclonal or polyclonal antibodies specific to the molecules of interest, or with supporting materials such as beads, especially agarose beads.

Other purification protocols can be envisaged. In 15 particular, for example when the molecules to be purified have 6 consecutive histidine residues, nickel-coated agarose beads can be used for purifying the molecules.

The purified molecules obtained are then incubated with the proteins possessing the binding sites for the Fc region.

20 Advantageously, these proteins are labelled for the purposes of detection, for example with a fluorophore.

When the molecule obtained does not have an antigenic peptide, and we wish to have available antigenic peptide/MHC 25 analogue complexes, it is incubated with the said peptide *in vitro*.

The study of the recombinant molecules according to the invention has demonstrated their great stability, and strong affinity in immunological recognition tests.

The invention thus provides tools that are of 30 considerable interest for modulating immunological processes.

In particular it relates to the use of antigenic peptide/class II MHC analogue complexes for counting and/or purifying the T lymphocytes that react with a given antigen

and for characterizing the phenotype of these cells, i.e. for determining or identifying the molecules that they secrete or that they express on their surface. This detection is carried out on a sample taken from a patient.

5 This can be a blood sample, or a sample taken from secondary lymphoid organs, such as the lymph nodes, the spleen, or from tumours.

These molecules can be used advantageously for counting or for purifying these cells from cellular suspensions as

10 described above.

Alternatively, they can be used for visualization of these cells in cell sections.

It is thus possible to determine the immunological status of an individual.

15 This application is of considerable interest for the development of vaccines against certain pathogens or of antitumour vaccines.

It is known that for judging the efficacy of a vaccine, the best method is to vaccinate a large number of

20 individuals and to monitor what becomes of this population when it is exposed to the infective agent in natural conditions. However, this approach is difficult, notably because of the considerable costs involved, and the difficulty of finding a sufficient number of volunteers.

25 The use of complexes according to the invention, as molecular probes that bind selectively to CD4⁺ T lymphocytes of given specificity, permits rapid comparison of the efficacy of different vaccine preparations and determination of the number and the optimum intervals between boosters.

30 In a preclinical study, individuals are inoculated with vaccine preparations containing the antigen or antigens, then a count is taken of the T cells present in a sample, that react with complexes according to the invention. The

response of the individuals makes it possible to assess the reaction to the antigenic peptide.

This application can also be employed as predictive means as to a patient's condition, by counting and 5 determining the phenotype of autoreactive T cells in patients at risk.

The invention thus makes it possible to determine the degree of progression of the disease in patients suffering from autoimmune diseases or to evaluate the efficacy of 10 certain treatments or therapeutic interventions.

The invention also relates to the application of the said multivalent complexes defined above in the diagnosis and development of treatments for autoimmune diseases.

A certain number of autoimmune diseases are due to the 15 mobilization of autoreactive T lymphocytes that cause the destruction of the organism's tissues. In some cases, for example in diabetics, the disease is diagnosed late, when the tissues are already destroyed. To prevent the destruction of tissues, and block the development of the 20 disease, it is essential to make an early diagnosis. The possibility of counting, by means of the invention, the autoreactive T lymphocytes in the blood of patients at risk constitutes a considerable advance.

Taking into account that the autoreactive T lymphocytes 25 play a decisive role in the development of autoimmune diseases, very many therapeutic strategies aim to eliminate these lymphocytes, or prevent them exerting their pathogenicity, it can be seen, that there is a great advantage in being able to count, by means of the invention, 30 the autoreactive T lymphocytes in the blood of treated patients, to compare the efficacy of different treatments, and to adapt the treatment according to the patient's response.

According to another aspect, the invention relates to the use of the complexes for enrichment in a given type of T cells.

This application makes it possible to have available 5 large quantities of specific T cells of a given antigen *in vitro* for purposes of cellular therapy. The patients can in fact be reinoculated with these cells for prevention or cure. Once again it is possible to count and determine, prior to inoculation, the phenotype of the complexed T 10 cells.

The invention further relates to the application of multivalent recombinant molecules as T-cell-stimulating agents.

An individual can be inoculated with these molecules in 15 order to stimulate the expansion and/or the activation of specific T cells of a given antigen in the absence of any other cell, in particular of presenting cells.

This use is therefore of interest for stimulating inadequate immune responses, for example with respect to 20 MHC/tumour antigen complexes.

In the case of infectious diseases, the recombinant molecules are inoculated *in vivo*, if necessary after a previous stage of propagation *ex vivo*.

Other characteristics and advantages of the invention 25 are given, purely for illustration, in the examples given below and refer to Figures 1 to 5, which show, respectively:

- Figure 1 shows the sequence of the cDNA insert of the α chain of the MHC,

30

- Figure 2 shows the plasmid construct containing the cDNA insert of Figure 1,

- Figure 3 shows the sequence of the cDNA insert of the β chain of the MHC,

5 - Figure 4 shows the plasmid construct containing the cDNA insert of Figure 3,

- Figure 5 shows the detailed plasmid construct of Figure 4, and

10 - Figure 6 shows a peptide/class II MHC octamer according to the invention.

Example 1: Production of peptide/class II MHC complexes

1. Construction of the recombinant plasmids

15 . cDNA construct coding for the IA α^d /Fc recombinant protein (clone 461) and insertion in a plasmid

This construct is illustrated by Figure 1 which gives the cDNA sequence, from position 420 to 1940, and that of the coded peptide (437-1921) (SEQ ID No. 1).

20 The cDNA comprises, linked together successively, the fragments coding for the signal peptide of IA α^d , IA $\alpha^d\alpha$, a linker, an acidic leucine zipper, a linker, a hinge region, the CH₂ region, then the CH₃ region of Fc.

25 This construct is inserted in the plasmid shown in Figure 2 and positioned for the control of a CuSO₄-inducible metallothionein promoter.

. cDNA construct coding for the recombinant protein LACK/IA β^d /leucine zipper (clone 268) and insertion in a plasmid

30 This construct is shown in Figure 3, which gives the cDNA sequence, from position 420 to 1370, and that of the coded peptide (440-1359) (SEQ ID No. 2).

The cDNA comprises successively the fragments, linked together, : coding for a leader sequence, β_1 , a LACK peptide (158-73), a linker, a thrombin site, a linker, IA β^d (β_1) IA β^d (β_2), a linker, a basic leucine zipper, a marker with 5 histidine units.

This construct is inserted in the plasmid shown in Figure 4, and shown in detail in Figure 5.

2. Transfection of the plasmids in Drosophila cells

3. Selection of stable transmitters

10 Stages 2 and 3 are carried out following the procedure according to (6).

4. Production and purification of the complexes

A) Production

15

The transfected Drosophila cells are cultured in 3-litre bottles, at 24°C, in an SFM Drosophila medium (GIBCO-BRL), supplemented with 1% of FCS (fetal calf serum).

20 When the cell density reaches 5×10^6 cells/ml, the production of LACK/IAd molecules is induced by adding CuSO₄ to a final concentration of 1 mM, then the medium is incubated for 5 to 6 days.

25 The supernatants are combined, and the cell debris is eliminated by centrifugation (20 min, 10K, 4°C). The supernatants are then transferred to tubes and centrifuged again.

30 The supernatants are concentrated 8 to 10-fold using a Prepscale® concentrator (Millipore, Inc.). Freezing is effected at -70°C until 500 ml of concentrated supernatants is obtained.

B) Purification

The supernatants are thawed at 37°C. Centrifugation is carried out for 15 minutes at 10K. The supernatants are then transferred to new tubes and are centrifuged again for 15 minutes at 10K.

5 They are then charged on an MK-D6 immunoaffinity column (bed volume 5 ml), equilibrated beforehand in a buffer A of 20 mM of sodium phosphate pH 7.0. The rate of elution is 10 to 20 ml/h.

10 The column is washed with 30 ml of buffer A (6 times the volume of the bed) at 0.5 ml/min.

For elution 15 ml of CAPS 50 mM pH 11.5 is used, operating by gravity.

15 fractions, each of 1 ml, are collected.

Each fraction is neutralized with 300 µl of sodium phosphate (200 mM, pH 6.2). Protease inhibitors (Complete^R, Roche Diagnostics) are added to each sample immediately.

The column is neutralized with buffer A.

20 To prevent aggregation of the peptide/MHC molecules, ion exchange chromatography is carried out immediately after elution.

The protein concentration in each fraction is determined by electrophoresis in denaturing gel.

The positive fractions are combined and loaded on an ion exchange column (Mono Q) (Pharmacia Biotech).

25 A buffer B is used: Tris-HCl 20 mM, pH 8.0, and a buffer C: Tris-HCl 20 mM pH 8.0 + 1 M NaCl.

Operation is effected with the following gradients:

0-5 min: 0% C; 5-20 min: 0-50% C; 20-21 min: 50-100% C; 21-25 min: 100% C; 25-26 min: 100% C; 26-30 min: 0% C.

30 The LACK/IA^d molecules generally elute to 30-36% in buffer C. The fractions corresponding to the elution peak are collected and the protein concentration is determined by electrophoresis in denaturing gel.

The positive fractions are combined and are dialysed at 4°C against 2 l of PBS, pH 7.4.

The dialysis buffer is changed twice in 24 h. The protein concentration is determined by the BCA test 5 (Biorad). The samples are frozen at -70°C in small fractions (8 µg). The yields are of the order of 0.5 mg/l of cellular supernatant.

C. Production of multivalent complexes (Figure 6)

10

A solution of protein A is prepared, coupled to a fluorophore consisting of Alexa 488^R (molecular probes # P-11047) at a concentration of 0.5 mg/ml in PBS 1 X, pH 7.4. (Protein A from Sigma)

15

100 µl aliquots are prepared and frozen at -20°C.

20

A peptide/MHC molecule aliquot (8 µg) is thawed and 1.1 µl of protein A coupled to the Alexa fluorophore is added. The mixture is incubated at room temperature for 30 min, then a PBS/BSA (bovine serum albumin) 0.1% mixture is added to give a final volume of 50 µl. 1 µl of mouse serum is added, and the product is used directly as staining reagent.

D. Flow cytofluorimetry

25

T cells from mouse lymph nodes are purified. 10⁶ cells are transferred to a tube and the staining reagent is added. Two hours later, the cells are washed in isotonic buffer and are analysed by flow cytofluorimetry. The frequency of cells 30 reacting with the staining reagent is determined by this method.

REFERENCES

1. Altman et al., *Science*, volume 274, 4 October 1996.
2. Scott et al., *J. Exp. Med.* 183:2087-2095, 1996.
- 5 3. Kalandadze et al., *J Biol Chem.* 271 (33): 20156-62, 1996.
4. Kozono et al., *Nature*. 369: 151-153, 1994.
5. Kozono et al., *Immunity*. 3: 187-196, 1995.
6. Sambrook et al., *Molecular Cloning: Second edition* 10 (1989).
7. Ausubel et al., *Current Protocols in Molecular Biology*, Publ. John Wiley & Sons Inc., 1997.

CLAIMS

1/ Soluble recombinant proteins, constituted as a minimum from a dimer that is itself formed from α and β chains of class I or II MHC molecules, comprising at the carboxy-terminal end of one or both chains, all or part of an Fc region of an immunoglobulin, these chains comprising if necessary leucine zippers, characterized in that they are combined in several dimers and in particular in tetramers or 10 in octamers and are complexed with natural or artificial proteins, comprising several binding sites for the constant regions of the immunoglobulins, such as protein A or protein G.

2/ Soluble recombinant proteins according to claim 1, 15 characterized in that they are bound covalently or noncovalently to an antigenic peptide.

3/ Soluble recombinant proteins according to claim 2, characterized in that the antigenic peptide is fixed to the amino-terminal end of the β chain by means of a flexible 20 arm.

4/ Nucleotide sequences having a reading frame corresponding to all or part of a protein according to any one of claims 1 to 3.

5/ Expression vectors, in particular plasmids, 25 characterized in that they have a sequence according to claim 4.

6/ Prokaryotic or eukaryotic cells carrying at least one vector according to claim 5.

7/ Use of proteins according to claim 2 or 3, for 30 counting and/or purifying the T lymphocytes that react with a given antigen and for characterizing the phenotype of these cells.

ART 34 AMDT

8/ Use according to Claim 7, as immunostimulating proteins, in particular for the development of vaccines.

9/ Use according to Claim 7, as a means of predicting a patient's condition, for counting and determining the 5 phenotype of autoreactive T cells in patients at risk, or for therapeutic purposes.

10/ Use according to claim 2 or 3, for the purification and/or enrichment of specific T lymphocytes of a given antigen, either from cell cultures, or from samples taken 10 from a patient.

11/ Populations of T lymphocytes enriched with a given type of T cells, such as those obtained according to claim 10, characterized in that they are intended to be used for the purposes of cellular therapy.

107048116
531 Rec'd PCIT 28 JAN 2002

ABSTRACT OF THE DISCLOSURE

The invention concerns soluble recombinant proteins, consisting at least of a dimer which is itself formed by \pm and 2 molecule chains of MHC class I or II. Said proteins are characterised in that they comprise at the carboxy-terminal end of one or both chains, all or part of a Fc region of immunoglobulin. The invention is applicable to recombinant proteins bound to an antigenic peptide in diagnosis or therapy.

RULE 63 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

RECOMBINANT PROTEINS AND MOLECULAR COMPLEXES DERIVED FROM THESE PROTEINS, ANALOGOUS TO MOLECULES INVOLVED IN IMMUNE RESPONSES

The specification of which (check applicable box(s))

is attached hereto
 was filed on January 28, 2002 as U.S. Application Serial No. as U.S. Application Serial No. (Att'y Dkt. No. 1721-47)
 was filed as PCT International application No. PCT/FR00/02193 on 28 July 2000
 and (if applicable to U.S. or PCT application) was amended on October 24, 2001

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or if no priority is claimed before the filing date of this application.

Priority Foreign Application(s)	Application Number	Country	Day/Month/Year Filed
			<u>29 July 1999</u>

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below

Application Number	Date/Month/Year Filed
<u>FR 99/09862</u>	<u>29 July 1999</u>

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT International Applications listed above or below

Prior U.S./PCT Application(s)	Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
	<u>PCT/FR00/02193</u>	<u>28 July 2000</u>	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (at the same address) individually and collectively owner(s)/owners' attorneys to prosecute this application and to transact all business attorneys thereof (at the same address) individually and collectively owner(s)/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent. Larry S. Nixon, 25640, Arthur H. Crawford, 25327, James T. Hosmer, 30184, Robert W. Faris, 31352, Richard G. Berne, 22770, Mark E. Nusbaum, 32348, Michael J. Keenan, 32106, Bryan H. Davidson, 30251, Stanley C. Spivner, 27393, Leonard C. Michard, 29009, Duane M. Byers, 33363, Jeffry H. Nelson, 30481, John R. Lastova, 30149, H. Warren Burnam, Jr. 29366, Mary J. Wilson, 32955, J. Scott Davidson, 33489, Alan M. Kagan, 36178, Robert A. Molan, 29834, B. J. Sadoff, 36663, James D. Bergquist, 34776, Updeep S. Gill, 37334, Michael J. Shoa, 34725, Donald L. Jackson, 41090, Michelle N. Lester, 32331, Frank P. Presta, 19828, Joseph S. Presta, 35129, Joseph A. Rhoa, 37515, Raymond Y. Mah, 41426, Chris Comunitis, 31097, Gary T. Tanu, 43180. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1	Inventor's Signature	<u>Nicolas</u>	Date <u>February 15, 2002</u>
	Inventor	<u>MI</u>	<u>France</u> (citizenship)
	Residence (city)	<u>Nice</u>	<u>GLAICHENHAUS</u>
	Mailing Address	<u>88, boulevard Manteiga Righi, Nice, FRANCE</u>	<u>(last)</u>
	(Zip Code)	<u>F-06100</u>	<u>FRANCE</u>
2	Inventor's Signature	<u>Laurent</u>	Date <u>February 15, 2002</u>
	Inventor	<u>MI</u>	<u>France</u> (citizenship)
	Residence (city)	<u>Valbonne</u>	<u>MAI HERGE</u>
	Mailing Address	<u>736 chemin des Ames du Purgatoire Résidence Le Guy, Valbonne, FRANCE</u>	<u>(last)</u>
	(Zip Code)	<u>F 06560</u>	<u>FRANCE</u>

See attached sheet(s) for additional inventor(s) information!!



10/048116

Rec'd PCT/PTO 24 MAY 2002

SEQUENCE LISTING

<110> C.N.R.S.

<120> RECOMBINANT PROTEINS AND MOLECULAR COMPLEXES DERIVED FROM THESE PROTEINS, ANALOGOUS TO MOLECULES INVOLVED IN IMMUNE RESPONSES

<130> CP/BB 1181

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 1484

<212> DNA

<213> Artificial sequence

<220>

<221> CDS

<222> (1)..(1482)

<220>

<223> Description of Artificial Sequence: ligation
fragments of DNA

<400> 1

atg	ccg	tgc	agc	aga	gct	ctg	att	ctg	ggg	gtc	ctc	gcc	ctg	aac	acc	48
Met	Pro	Cys	Ser	Arg	Ala	Leu	Ile	Leu	Gly	Val	Leu	Ala	Leu	Asn	Thr	
1							5				10			15		

atg	ctc	agc	ctc	tgc	gga	ggt	gaa	gac	gac	att	gag	gcc	gac	cac	gta	96
Met	Leu	Ser	Leu	Cys	Gly	Gly	Glu	Asp	Asp	Ile	Glu	Ala	Asp	His	Val	
20							25				30					

ggc	ttc	tat	ggt	aca	act	gtt	tat	cag	tct	gga	gac	att	ggc	cag	144	
Gly	Phe	Tyr	Gly	Thr	Thr	Val	Tyr	Gln	Ser	Pro	Gly	Asp	Ile	Gly	Gln	
35							40				45					

tac	aca	cat	gaa	ttt	gat	ggt	gat	gag	ttg	ttc	tat	gtg	gac	ttg	gat	192
Tyr	Thr	His	Glu	Phe	Asp	Gly	Asp	Glu	Leu	Phe	Tyr	Val	Asp	Leu	Asp	
50							55				60					

aag	aag	aaa	act	gtc	tgg	agg	ctt	cct	gag	ttt	ggc	caa	ttg	ata	ctc	240
Lys	Lys	Lys	Thr	Val	Trp	Arg	Leu	Pro	Glu	Phe	Gly	Gln	Leu	Ile	Leu	
65							70				75			80		

ttt	gag	ccc	caa	ggt	'gga	ctg	caa	aac	ata	gct	gca	gaa	aaa	cac	aac	288
Phe	Glu	Pro	Gln	Gly	Gly	Leu	Gln	Asn	Ile	Ala	Ala	Glu	Lys	His	Asn	
85							90				95					

ttg	gga	atc	ttg	act	aag	agg	tca	aat	ttc	acc	cca	gct	acc	aat	gag	336
Leu	Gly	Ile	Leu	Thr	Lys	Arg	Ser	Asn	Phe	Thr	Pro	Ala	Thr	Asn	Glu	
100							105				110					

gct cct caa gcg act gtg ttc ccc aag tcc cct gtg ctg ctg ggt cag	384
Ala Pro Gln Ala Thr Val Phe Pro Lys Ser Pro Val Leu Leu Gly Gln	
115 120 125	
ccc aac acc ctt atc tgc ttt gtg gac aac atc ttc cca cct gtg atc	432
Pro Asn Thr Leu Ile Cys Phe Val Asp Asn Ile Phe Pro Pro Val Ile	
130 135 140	
aac atc aca tgg ctc aga aat agc aag tca gtc aca gac ggc gtt tat	480
Asn Ile Thr Trp Leu Arg Asn Ser Lys Ser Val Thr Asp Gly Val Tyr	
145 150 155 160	
gag acc agc ttc ctc gtc aac cgt gac cat tcc ttc cac aag ctg tct	528
Glu Thr Ser Phe Leu Val Asn Arg Asp His Ser Phe His Lys Leu Ser	
165 170 175	
tat ctc acc ttc atc cct tct gat gat gac att tat gac tgc aag gtg	576
Tyr Leu Thr Phe Ile Pro Ser Asp Asp Ile Tyr Asp Cys Lys Val	
180 185 190	
gag cac tgg ggc ctg gag gag ccg gtt ctg aaa cac tgg gaa cct gag	624
Glu His Trp Gly Leu Glu Pro Val Leu Lys His Trp Glu Pro Glu	
195 200 205	
att cca gcc ccc atg tca gag ctg aca gaa act gga ggt gga gga tcc	672
Ile Pro Ala Pro Met Ser Glu Leu Thr Glu Thr Gly Gly Gly Ser	
210 215 220	
act aca gct cca tca gct cag ctc gaa aaa gag ctc cag gcc ctg gag	720
Thr Thr Ala Pro Ser Ala Gln Leu Glu Lys Glu Leu Gln Ala Leu Glu	
225 230 235 240	
aag gaa aat gca cag ctg gaa tgg gag ttg caa gca ctg gaa aag gaa	768
Lys Glu Asn Ala Gln Leu Glu Trp Glu Leu Gln Ala Leu Glu Lys Glu	
245 250 255	
ctg gct cag gca gca tct gag ccc aga ggg ccc aca atc aag ccc tgt	816
Leu Ala Gln Ala Ala Ser Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys	
260 265 270	
cct cca tgc aaa tgc cca gca cct aac ctc ttg ggt gga cca tcc gtc	864
Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val	
275 280 285	
ttc atc ttc cct cca aag atc aag gat gta ctc atg atc tcc ctg agc	912
Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser	
290 295 300	
ccc ata gtc aca tgt gtg gtg gat gtg agc gag gat gac cca gat	960
Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp	
305 310 315 320	
gtc cag atc agc tgg ttt gtg aac aac gtg gaa gta cac aca gct cag	1008
Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln	
325 330 335	

aca caa acc cat aga gag gat tac aac agt act ctc cgg gtg gtc agt	1056
Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser	
340 345 350	
gcc ctc ccc atc cag cac cag gac tgg atg agt ggc aag gag ttc aaa	1104
Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys	
355 360 365	
tgc aag gtc aac aac aaa gac ctc cca gcg ccc atc gag aga acc atc	1152
Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile	
370 375 380	
tca aaa ccc aaa ggg tca gta aga gct cca cag gta tat gtc ttg cct	1200
Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro	
385 390 395 400	
cca cca gaa gaa gag atg act aag aaa cag gtc act ctg acc tgc atg	1248
Pro Pro Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met	
405 410 415	
gtc aca gac ttc atg cct gaa gac att tac gtg gag tgg acc aac aac	1296
Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn	
420 425 430	
ggg aaa aca gag cta aac tac aag aac act gaa cca gtc ctg gac tct	1344
Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser	
435 440 445	
gat ggt tct tac ttc atg tac agc aag ctg aga gtg gaa aag aag aac	1392
Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn	
450 455 460	
tgg gtg gaa aga aat agc tac tcc tgt tca gtg gtc cac gag ggt ctg	1440
Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu	
465 470 475 480	
cac aat cac cac acg act aag agc ttc tcc cgg act ccg ggt aa	1484
His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly	
485 490	

<210> 2
<211> 921
<212> DNA
<213> Artificial sequence

<220>
<223> Description of artificial sequence: Ligation
fragments of DNA

<220>
<221> CDS
<222> (1)..(921)

<400> 2
atg gct ctg cag atc ccc agc ctc ctc ctc tca gct gct gtg gtg gtg 48

Met Ala Leu Gln Ile Pro Ser Leu Leu Leu Ser Ala Ala Val Val Val	1	5	10	15
ctg atg gtg ctg agc agc ccc ggg act gag ggc gga aac tcc atc tgc				96
Leu Met Val Leu Ser Ser Pro Gly Thr Glu Gly Gly Asn Ser Ile Cys				
20	25	30		
ttc tcg ccg tcg ctg gag cac ccg atc gtg gtg tcc ggc agc tgg gac				144
Phe Ser Pro Ser Leu Glu His Pro Ile Val Val Ser Gly Ser Trp Asp				
35	40	45		
gga ggt ggg ggc tca cta gtg ccc cga ggc tct gga ggt gga ggc tcc				192
Gly Gly Gly Ser Leu Val Pro Arg Gly Ser Gly Gly Gly Ser				
50	55	60		
gaa agg cat ttc gtg gtc cag ttc aag ggc gag tgc tac tac acc aac				240
Glu Arg His Phe Val Val Gln Phe Lys Gly Glu Cys Tyr Tyr Thr Asn				
65	70	75	80	
ggg acg cag cgc ata cgg ctc gtg acc aga tac atc tac aac cgg gag				288
Gly Thr Gln Arg Ile Arg Leu Val Thr Arg Tyr Ile Tyr Asn Arg Glu				
85	90	95		
gag tac gtg cgc tac gac agc gac gtg ggc gag tac cgc gcg gtg acc				336
Glu Tyr Val Arg Tyr Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr				
100	105	110		
gag ctg ggg cgg cca gac gcc gag tac tgg aac agc cag cgg gag atc				384
Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Pro Glu Ile				
115	120	125		
ctg gag cga acg cgg gcc gag gtg gac acg gcg tgc aga cac aac tac				432
Leu Glu Arg Thr Arg Ala Glu Val Asp Thr Ala Cys Arg His Asn Tyr				
130	135	140		
gag ggg ccc gag acc agc acc tcc ctg cgg cgg ctt gaa cag ccc aat				480
Glu Gly Pro Glu Thr Ser Thr Ser Leu Arg Arg Leu Glu Gln Pro Asn				
145	150	155	160	
gtc gcc atc tcc ctg tcc agg aca gag gcc ctc aac cac cac aac act				528
Val Ala Ile Ser Leu Ser Arg Thr Glu Ala Leu Asn His His Asn Thr				
165	170	175		
ctg gtc tgt tcg gtg aca gat ttc tac cca gcc aag atc aaa gtg cgc				576
Leu Val Cys Ser Val Thr Asp Phe Tyr Pro Ala Lys Ile Lys Val Arg				
180	185	190		
tgg ttc agg aat ggc cag gag aca gtg ggg gtc tca tcc aca cag				624
Trp Phe Arg Asn Gly Gln Glu Glu Thr Val Gly Val Ser Ser Thr Gln				
195	200	205		
ctt att agg aat ggg gac tgg acc ttc cag gtc ctg gtc atg ctg gag				672
Leu Ile Arg Asn Gly Asp Trp Thr Phe Gln Val Leu Val Met Leu Glu				
210	215	220		
atg acc cct cat cag gga gag gtc tac acc tgc cat gtg gag cat ccc				720
Met Thr Pro His Gln Gly Glu Val Tyr Thr Cys His Val Glu His Pro				

225 230 235 240 768
agc ctg aag agc ccc atc act gtg gag tgg agg gca cag tcc gag tct
Ser Leu Lys Ser Pro Ile Thr Val Glu Trp Arg Ala Gln Ser Glu Ser
245 250 255
gcc cg^g agc aag gga ggt gga gga tcc act aca gct cca tca gct cag 816
Ala Arg Ser Lys Gly Gly Gly Ser Thr Thr Ala Pro Ser Ala Gln
260 265 270
ttg aaa aag aaa ttg caa gca ctg aag aaa aag aac gct cag ctg aag 864
Leu Lys Lys Leu Gln Ala Leu Lys Lys Lys Asn Ala Gln Leu Lys
275 280 285
tgg aaa ctt caa gcc ctc aag aag aaa ctc gcc cag cat cat cat cat 912
Trp Lys Leu Gln Ala Leu Lys Lys Leu Ala Gln His His His His
290 295 300
cat cat tga 921
His His
305